News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MacroGenics, Inc. (MGNX) To Present Pre-Clinical Data On MGD007 At The American Association for Cancer Research Annual Meeting


3/31/2014 9:22:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., March 31, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that pre-clinical data on its colorectal cancer product candidate, MGD007, will be presented at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The poster, titled "Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer," will be presented Sunday, April 6, 2014, from 1:00-5:00pm PT in Hall A-E, poster section 28, poster number 26.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES